|Bid||84.56 x N/A|
|Ask||88.88 x N/A|
|Day's range||86.21 - 87.12|
|52-week range||72.84 - 89.28|
|Beta (5Y monthly)||0.55|
|PE ratio (TTM)||21.81|
|Forward dividend & yield||3.10 (3.62%)|
|Ex-dividend date||08 Mar 2022|
|1y target est||N/A|
Positive opinion could expand the role of Cosentyx® (secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EUSafety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indicationsSince its initial approval, Cosentyx has a proven sustained efficacy profile across several systemic inflammatory conditions and has treated more than 700,000 patients worldwide 1-11 Ba
Alnylam's (ALNY) portfolio of approved drugs is witnessing strong uptake so far while its pipeline is progressing well. However, stiff competition in the target market remains a woe.
Novartis can provide investors with a market-crushing 3.8% dividend yield -- and that isn't all the stock has to offer.